No Data
Jiangsu Jindick Biotechnology Co., Ltd. Report for the Third Quarter of 2024
Jindike (688670.SH) released its performance for the first three quarters, with a net loss of 53.4614 million yuan.
Jindike (688670.SH) released the third quarter report of 2024, with revenue in the first three quarters of the company reaching 388...
Jindike (688670.SH): The net loss for the first three quarters was 53.46 million yuan.
On October 24th, Golden Dick (688670.SH) released its third quarter report, with revenue of 38.899 million yuan, a year-on-year decrease of 67.81%, net loss of 53.46 million yuan, non-recurring net loss of 61.53 million yuan, and basic earnings per share of -0.43 yuan.
Kindik (688670.SH): There are currently no related products or research projects for monkeypox vaccines.
On September 20th, Golden Dick (688670.SH) stated on the investor interaction platform that the company currently has no monkeypox vaccine-related products or research and development projects. Investors are reminded to invest cautiously and be aware of investment risks.
A-share vaccine stocks fell, with Kindicare down more than 10%.
On August 28th, Gelonghui reported that Jindike fell more than 10%, cansino biologics inc., Hualan Biotech, Qingdao Vland Biotech Inc., Baike Biotech, Beijing Bohui Innovation Biotechnology Group, and others followed suit.
Express News | Star Market Closing Analysis: SSE Science and Technology Innovation Board 50 Index fell by 1.19%. Biomedical and medical instruments sectors were locally active.
No Data
No Data